dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Federal de Minas Gerais (UFMG)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:30:51Z
dc.date.accessioned2022-10-05T19:01:40Z
dc.date.available2014-05-27T11:30:51Z
dc.date.available2022-10-05T19:01:40Z
dc.date.created2014-05-27T11:30:51Z
dc.date.issued2013-10-14
dc.identifierRevista Brasileira de Psiquiatria, v. 35, n. 3, p. 284-294, 2013.
dc.identifier1516-4446
dc.identifierhttp://hdl.handle.net/11449/76840
dc.identifier10.1590/1516-4446-2012-3505
dc.identifierS1516-4446-2012-3505
dc.identifierWOS:000326034600015
dc.identifier2-s2.0-84885119225
dc.identifier2-s2.0-84885119225.pdf
dc.identifier7964386240653380
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3925715
dc.description.abstractTo present a critical review of publications reporting on the rationale and clinical implications of the use of biomarkers for the early diagnosis of Alzheimer's disease (AD). Methods: We conducted a systematic search of the PubMed and Web of Science electronic databases, limited to articles published in English between 1999 and 2012, and based on the following terms: mild cognitive impairment, Alzheimer's disease OR dementia, biomarkers. We retrieved 1,130 articles, of which 175 were reviews. Overall, 955 original articles were eligible. Results: The following points were considered relevant for the present review: a) rationale for biomarkers research in AD and mild cognitive impairment (MCI); b) usefulness of distinct biomarkers for the diagnosis and prediction of AD; c) the role of multimodality biomarkers for the diagnosis and prediction of AD; d) the role of biomarkers in clinical trials of patients with AD and MCI; and e) current limitations to the widespread use of biomarkers in research and clinical settings. Conclusion: Different biomarkers are useful for the early diagnosis and prediction of AD in at-risk subjects. Nonetheless, important methodological limitations need to be overcome for widespread use of biomarkers in research and clinical settings. © 2013 Associação Brasileira de Psiquiatria.
dc.languageeng
dc.relationRevista Brasileira de Psiquiatria
dc.relation2.093
dc.relation0,803
dc.rightsAcesso aberto
dc.sourceScopus
dc.subjectAlzheimer's disease
dc.subjectAmyloid-β protein
dc.subjectBiomarkers
dc.subjectMild cognitive impairment
dc.subjectNeuroimaging
dc.subjectTau protein
dc.titleMild cognitive impairment (part 2): Biological markers for diagnosis and prediction of dementia in Alzheimer's disease
dc.typeArtigo


Este ítem pertenece a la siguiente institución